Embargo finished.
http://my.americanheart.org/idc/gro...p/@scon/documents/downloadable/ucm_469640.pdf
I honestly thought Lonestar would have better results than this. I don't think their viable on these results( just my non medical non scientific etc. etc opinion)
Peak VO@
Very poor VO2 for a 60+ is < 20.51
http://www.machars.net/v02max.htm
Algisyl- LVR increase from 12.4 to 13.2 (still very poor)
We know marginal improvements can make significant improvements in a patients life (result is statistically significant), but as a PRIMARY END POINT, to me it appears very underwhelming.
6 Minute Walk
OK statistically significant.
NYHA
Over 6 months a general an improvement of 1 class, pretty good.
20% deteriorated HF in Control 10% in Implant. (Is that good enough?)
Adverse Events
Very significantly higher in Implant group
20% of patients in the Implant group had a major surgical complication.
(Would find it hard to believe that Algisyl- LVR is viable with this level of serious surgical complications)
Deaths.
This is one of the things that sunk Acorn, the device didn't improve survivability, may have even increased deaths.
5% target 8% actual, while within variability, doesn't dispel the cloud that Algisyl- LVR may adversely affect survivability.
Looks like a dead end to me.
- Forums
- ASX - By Stock
- SHC
- Lonestar Algisyl-LVR
Lonestar Algisyl-LVR, page-8
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SHC (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non Executive Director
Simon Kidston
Non Executive Director
SPONSORED BY The Market Online